[go: up one dir, main page]

MX2019007492A - Composiciones de celulas t deficientes del receptor de celulas t. - Google Patents

Composiciones de celulas t deficientes del receptor de celulas t.

Info

Publication number
MX2019007492A
MX2019007492A MX2019007492A MX2019007492A MX2019007492A MX 2019007492 A MX2019007492 A MX 2019007492A MX 2019007492 A MX2019007492 A MX 2019007492A MX 2019007492 A MX2019007492 A MX 2019007492A MX 2019007492 A MX2019007492 A MX 2019007492A
Authority
MX
Mexico
Prior art keywords
lymphocytes
deficient
tcr
cell
compositions
Prior art date
Application number
MX2019007492A
Other languages
English (en)
Other versions
MX386776B (es
Inventor
L Sentman Charles
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of MX2019007492A publication Critical patent/MX2019007492A/es
Publication of MX386776B publication Critical patent/MX386776B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se dirige a linfocitos T modificados, métodos para elaborar y utilizar linfocitos T modificados y aislados, y métodos para utilizar estos linfocitos T modificados y aislados para tratar enfermedades y trastornos. En una modalidad, esta invención se relaciona ampliamente con los linfocitos T con deficiencia de TCR, poblaciones aisladas de estos, y composiciones que los comprenden. En otra modalidad de la invención, estos linfocitos T con deficiencia de TCR se diseñan para expresar un receptor funcional que no es TCR. La invención también se refiere a métodos para elaborar dichos linfocitos T con deficiencia de TCR, y métodos para reducir o mejorar, o prevenir o tratar, enfermedades y trastornos utilizando dichos linfocitos T con deficiencia de TCR, poblaciones de estos, o composiciones que las comprenden.
MX2019007492A 2012-04-30 2013-04-30 Composiciones de células t deficientes del receptor de células t. MX386776B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/459,664 US9273283B2 (en) 2009-10-29 2012-04-30 Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PCT/US2013/038921 WO2013166051A1 (en) 2012-04-30 2013-04-30 T cell receptor-deficient t cell compositions

Publications (2)

Publication Number Publication Date
MX2019007492A true MX2019007492A (es) 2019-09-06
MX386776B MX386776B (es) 2025-03-19

Family

ID=49515059

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013118A MX366018B (es) 2012-04-30 2013-04-30 Composiciones de células t deficientes del receptor de células t.
MX2019007492A MX386776B (es) 2012-04-30 2013-04-30 Composiciones de células t deficientes del receptor de células t.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014013118A MX366018B (es) 2012-04-30 2013-04-30 Composiciones de células t deficientes del receptor de células t.

Country Status (11)

Country Link
US (3) US9273283B2 (es)
EP (3) EP2844742B1 (es)
JP (2) JP6411328B2 (es)
CN (3) CN108795875B (es)
AU (2) AU2013256424B2 (es)
BR (1) BR112014027155B1 (es)
CA (1) CA2871955C (es)
ES (2) ES2711629T3 (es)
MX (2) MX366018B (es)
RU (1) RU2653761C2 (es)
WO (1) WO2013166051A1 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US12492376B2 (en) * 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
JP6389166B2 (ja) 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2930784C (en) * 2013-11-22 2023-01-31 Cellectis Method for generating batches of allogeneic t cells with averaged potency
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
AU2015339743C1 (en) 2014-10-31 2021-04-22 The Trustees Of The University Of Pennsylvania Altering gene expression in modified T cells and uses thereof
KR20180041087A (ko) * 2014-12-02 2018-04-23 프로스펙트 차터케어 알더블유엠씨, 엘엘씨 디/비/에이 로저 윌리암스 메디컬 센터 암을 치료하기 위한 방법 및 조성물
CA2972597A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
JP6895380B2 (ja) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
RS64397B1 (sr) 2015-03-27 2023-08-31 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
AU2016297014B2 (en) * 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
CN106554414B (zh) * 2015-09-18 2019-04-23 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
IL295398B2 (en) * 2015-10-23 2025-01-01 Eureka Therapeutics Inc Antibody/T-cell receptor chimeric constructs and their uses
AU2016362129A1 (en) 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US20200255864A1 (en) * 2016-03-19 2020-08-13 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
MA45478A (fr) * 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
SG11201808831TA (en) 2016-04-15 2018-11-29 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
JP6987080B2 (ja) 2016-05-05 2021-12-22 サウスウェスト リサーチ インスティテュート 細胞増殖のための三次元バイオリアクター及び関連用途
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
WO2018049095A1 (en) * 2016-09-09 2018-03-15 The Feinstein Institute For Medical Research Methods of treating hypertension
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
CN110022907A (zh) * 2016-10-10 2019-07-16 国家生物技术研究所公司 非细胞毒性的修饰细胞及其用途
US11440958B2 (en) 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
WO2018233596A1 (zh) 2017-06-20 2018-12-27 江苏恒瑞医药股份有限公司 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA
AU2018292181B2 (en) * 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
JP2020530291A (ja) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
MX2020002901A (es) 2017-09-19 2020-07-22 Massachusetts Inst Technology Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2019071358A1 (en) * 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
EP3720950B1 (en) * 2017-12-05 2025-09-03 Celyad S.A. Reducing fratricide of immune cells expressing nkg2d-based receptors
WO2019110693A1 (en) * 2017-12-05 2019-06-13 Celyad S.A. Compositions and methods for improving persistence of cells for adoptive transfer
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
KR20250150659A (ko) * 2017-12-29 2025-10-20 메모리얼 슬로안 케터링 캔서 센터 향상된 키메라 항원 수용체 및 그의 용도
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
AU2019216982B2 (en) * 2018-02-11 2024-07-04 Memorial Sloan-Kettering Cancer Center Non-HLA restricted T cell receptors and uses thereof
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
US20210309713A1 (en) * 2018-04-04 2021-10-07 Daren Biotech Limited Chimeric Antigen Receptor and Method for Treating Cancers
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
JP7721436B2 (ja) 2018-04-12 2025-08-12 ウモジャ バイオファーマ インコーポレイテッド ウイルスベクター及びパッケージング細胞株
KR20210008408A (ko) 2018-05-23 2021-01-21 싱가포르국립대학교 T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12359169B2 (en) 2018-06-20 2025-07-15 Shanghai Longyao Biotechnology Inc., Ltd. Universal CAR-T cell and preparation method and use thereof
CN110616188B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种通用型car-t细胞及其制备方法和应用
TW202020146A (zh) * 2018-07-26 2020-06-01 大陸商南京傳奇生物科技有限公司 含nef之t細胞及其產生方法
US11447731B2 (en) 2018-09-24 2022-09-20 Southwest Research Institute Three-dimensional bioreactors
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020103013A1 (en) * 2018-11-21 2020-05-28 Nanjing Bioheng Biotech Co., Ltd Modified t cells and uses thereof
US12227551B2 (en) 2018-12-11 2025-02-18 Obsidian Therapeutics, Inc. Membrane bound IL12 compositions and methods for tunable regulation
CN111378624B (zh) * 2018-12-29 2023-10-20 深圳市第三人民医院 一种靶向性抗肿瘤t细胞及其制备方法和应用
SG11202109172TA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Human carbonic anhydrase 2 compositions and methods for tunable regulation
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
BR112021025022A2 (pt) 2019-06-12 2022-02-22 Obsidian Therapeutics Inc Composições de ca2 e métodos para regulação ajustáveis
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN114450414A (zh) * 2019-07-30 2022-05-06 大学健康网络 T细胞受体及其使用方法
CN120624368A (zh) * 2019-08-29 2025-09-12 克莱格医学有限公司 抗移植反应的细胞和方法
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
AU2021205416A1 (en) 2020-01-08 2022-08-25 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
WO2021150919A1 (en) 2020-01-23 2021-07-29 The Children's Medical Center Corporation Stroma-free t cell differentiation from human pluripotent stem cells
KR20240096884A (ko) 2020-03-10 2024-06-26 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2022005462A1 (en) * 2020-06-30 2022-01-06 Tr1X, Inc. Poly-donor cd4+ t cells expressing il-10 and uses thereof
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4508073A1 (en) 2022-04-14 2025-02-19 Board of Regents of the University of Nebraska Cell therapy for alzheimer's disease
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
CN115747166B (zh) * 2022-10-13 2024-12-06 上海怡豪生物科技有限公司 一种通用型car-t细胞及其制备方法与应用
CN117883478B (zh) * 2024-03-14 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 非经典t细胞在制备治疗脊髓损伤的药物中的用途

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133433A (en) 1984-07-27 2000-10-17 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US6242567B1 (en) 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5667967A (en) 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
IL86278A (en) 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
US6464978B1 (en) 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US5415874A (en) 1989-10-31 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Natural killer cell lines and clones with antigen specificity
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6416971B1 (en) 1990-05-15 2002-07-09 E.R. Squibb & Sons, Inc. Soluble single chain T cell receptors
US6407221B1 (en) 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
FR2672901B1 (fr) 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
JP3238447B2 (ja) 1991-12-31 2001-12-17 株式会社エスアールエル ヒト白血球株化細胞
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US6172278B1 (en) * 1992-09-14 2001-01-09 The General Hospital Corporation Ikaros transgenic cells and mice
DK0692026T3 (da) 1993-04-09 1999-09-27 Pfizer En human T-cellereceptor fra den G-proteinkoblede receptorfamilie
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5552300A (en) 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
DE4408999A1 (de) 1994-03-16 1995-09-28 Braun Melsungen Ag Humane T-Zellrezeptoren zur diagnostischen sowie therapeutischen Verwendung bei autoimmunem Diabetes mellitus
EP0758394B1 (en) 1994-05-02 2002-11-20 Bernd Groner Bifunctional protein, preparation and use
WO1996013584A1 (en) 1994-11-01 1996-05-09 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
CA2209300C (en) 1995-02-24 2011-06-28 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
DE19540515C1 (de) 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
WO1997032603A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
DE19625191A1 (de) 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
CA2269738A1 (en) 1996-10-25 1998-05-07 Mitchell H. Finer Targeted cytolysis of cancer cells
US20040038894A1 (en) * 1996-12-31 2004-02-26 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Compounds for modulating cell negative regulations and biological applications thereof
WO1998041613A1 (en) 1997-03-14 1998-09-24 Otten Gillis R Targeted cytolysis of cancer cells
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
CA2357035A1 (en) 1998-12-29 2000-07-06 University Of Vermont And State Agricultural College Use of cd40 engagement to alter t cell receptor usage
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
US6770749B2 (en) 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
US6953576B2 (en) 2000-08-21 2005-10-11 University Health Network Method of modulating tumor immunity
EP1188825A1 (en) 2000-09-18 2002-03-20 Universiteit Leiden T cell receptor transfer into a candidate effector cell or a precursor thereof
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US20030069199A1 (en) * 2000-12-07 2003-04-10 Hanan Polansky Treatment methods based on microcompetition for a limiting GABP complex
US20030104358A1 (en) * 2000-12-07 2003-06-05 Hanan Polansky Diagnosis methods based on microcompetition for a limiting GABP complex
US20030068616A1 (en) * 2000-12-07 2003-04-10 Hanan Polansky Drug discovery assays based on microcompetition for a limiting GABP complex
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
IL141539A0 (en) 2001-02-20 2002-03-10 Yeda Res & Dev Dna molecules and cells transfected therewith
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
CA2487779C (en) 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US7763243B2 (en) 2001-08-17 2010-07-27 Roger Williams Medical Center In situ immunization
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20060269529A1 (en) 2002-05-07 2006-11-30 Niederman Thomas M Modified t lymphocytes and uses therefor
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003270063A1 (en) 2002-09-04 2004-03-29 The Trustees Of The University Of Pennsylvania Immune cell receptor ligand and immune cell receptor
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
DE10259713A1 (de) 2002-12-19 2004-07-08 Johannes-Gutenberg-Universität Mainz Verfahren zur Expressionsstabilisierung und Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigenerkennenden genetischen Konstrukten (scARC) und entsprechend mutierten MDM2-Protein spezifischen scT-Zell Rezeptoren
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005019420A2 (en) 2003-08-20 2005-03-03 St. Jude Children's Research Hospital Chimeric receptors with disrupted dileucine motifs
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ATE408684T1 (de) 2004-05-19 2008-10-15 Medigene Ltd Verfahren zur verbesserung von t-zellrezeptoren
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
WO2006007539A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
EP3530321A1 (en) 2004-12-10 2019-08-28 Peter MacCallum Cancer Institute Methods and compositions for adoptive immunotherapy
WO2006103429A2 (en) 2005-04-01 2006-10-05 Medigene Limited High affinity hiv t cell receptors
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
DK1910521T3 (da) 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
PT2016102E (pt) 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
EP1870418A1 (en) 2006-06-20 2007-12-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Allorestricted peptide-specific T cells
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
EP1878744A1 (en) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
DE102006041455B4 (de) 2006-09-04 2011-07-28 Johannes-Gutenberg-Universität Mainz, 55122 Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP1932537A1 (en) 2006-12-12 2008-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Expression of transgenic T cell receptors in LAK-T cells
US7508404B2 (en) 2006-12-21 2009-03-24 Eastman Kodak Company Thermal printer with two print heads
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
HRP20161191T1 (hr) * 2007-01-31 2016-11-18 Yeda Research And Development Company Limited Preusmjerene, genetski projektirane t regulacijske stanice i njihova uporaba u suspenziji autoimunih i upalnih bolesti
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US20110213288A1 (en) * 2007-04-23 2011-09-01 The Board Of Regents, The University Of Texas System Device And Method For Transfecting Cells For Therapeutic Uses
EP3031916B1 (en) 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
EP3241846B1 (en) 2007-10-04 2022-02-23 ZymoGenetics, Inc. B7 family member zb7h6 and related compositions and methods
GB0721686D0 (en) 2007-11-05 2007-12-12 Medinnova As Polypeptides
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2010012829A1 (en) 2008-07-31 2010-02-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Her2/neu specific t cell receptors
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US8835617B2 (en) 2008-11-06 2014-09-16 The Trustees Of Columbia University In The City Of New York Polynucleotides encoding a human TRIM-Cyp fusion polypeptide, compositions thereof, and methods of using same
EP2186825A1 (en) 2008-11-13 2010-05-19 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Human-derived T cell receptors
EP2352756B1 (en) 2008-11-24 2012-09-19 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH High affinity t cell receptor and use thereof
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
FR2941858B1 (fr) 2009-02-10 2011-03-11 Charam Khosrvaninejad Dispositif chirurgical apte a realiser la protection temporaire d'une anastomose
WO2010107400A1 (en) 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
WO2010140862A2 (ko) * 2009-06-05 2010-12-09 Seol Dai-Wu 단일 또는 멀티 표적 유전자를 억제하는 멀티-시스트로닉 ｓｈＲＮＡ 발현 카세트
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US10138276B2 (en) * 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011064664A2 (en) 2009-11-24 2011-06-03 Chrontech Pharma Ab T cell receptors specific for immunodominant ctl epitopes of hcv
PT2510011E (pt) 2009-12-09 2014-12-12 Inst Nat Santé Et De La Rech Médicale Anticorpos monoclonais que se ligam a b7h6 e suas utilizações
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
US8945868B2 (en) * 2010-07-21 2015-02-03 Sangamo Biosciences, Inc. Methods and compositions for modification of a HLA locus
EP2598528A1 (en) 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
WO2012058460A2 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
RU2014129863A (ru) * 2011-12-21 2016-02-10 Модерна Терапьютикс, Инк. Способы повышения жизнеспособности или увеличения продолжительности жизни органа или экспланта органа
DK3473707T3 (da) * 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
AU2014296059B2 (en) 2013-08-02 2020-12-10 The Regents Of The University Of California Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
CA2937750A1 (en) * 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3466967A1 (en) * 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2016297014B2 (en) * 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
PH12018502203B1 (en) * 2016-04-15 2024-05-15 Immunext Inc Anti-human vista antibodies and use thereof
US12060394B2 (en) * 2016-04-28 2024-08-13 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
KR20190127892A (ko) * 2017-03-22 2019-11-13 노파르티스 아게 바이오마커 및 효능이 증진된 car t 세포 요법
US11566223B2 (en) * 2017-06-01 2023-01-31 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cell preparation and uses thereof
JP2020530291A (ja) * 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
JP7343483B2 (ja) * 2017-09-08 2023-09-12 ユニバーシティー ヘルス ネットワーク Ｐｏｌｏ様キナーゼ４の阻害のための併用療法
WO2019075385A1 (en) * 2017-10-12 2019-04-18 Board Of Regents, The University Of Texas System T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
DE112019000348B4 (de) * 2018-01-05 2021-10-28 Nantbio, Inc. Umprogrammierte t-zellen ähnliche nk-zellen
TW202020146A (zh) * 2018-07-26 2020-06-01 大陸商南京傳奇生物科技有限公司 含nef之t細胞及其產生方法
CA3107675A1 (en) * 2018-07-30 2020-02-06 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies
JP7671248B2 (ja) * 2018-12-05 2025-05-01 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
US11858977B2 (en) * 2019-10-24 2024-01-02 Innovative Cellular Therapeutics Holdings, Ltd. Modified TCR and uses thereof

Also Published As

Publication number Publication date
JP2018157824A (ja) 2018-10-11
JP6805204B2 (ja) 2020-12-23
AU2018253624B2 (en) 2021-05-13
US20160312182A1 (en) 2016-10-27
EP2844742A1 (en) 2015-03-11
CN104395463A (zh) 2015-03-04
BR112014027155A2 (pt) 2017-08-08
JP6411328B2 (ja) 2018-10-24
MX386776B (es) 2025-03-19
ES2711629T3 (es) 2019-05-06
JP2015516818A (ja) 2015-06-18
RU2653761C2 (ru) 2018-05-14
WO2013166051A1 (en) 2013-11-07
CN108795875B (zh) 2023-06-23
US20120302466A1 (en) 2012-11-29
CN108384758A (zh) 2018-08-10
EP2844742A4 (en) 2015-09-23
RU2018111729A3 (es) 2021-12-22
EP3447125B1 (en) 2021-04-07
HK1207882A1 (en) 2016-02-12
CN108384758B (zh) 2022-06-24
AU2013256424A1 (en) 2014-12-18
EP3904503A1 (en) 2021-11-03
CN108795875A (zh) 2018-11-13
AU2018253624A1 (en) 2018-11-22
RU2014148136A (ru) 2016-06-20
MX2014013118A (es) 2015-07-14
US9273283B2 (en) 2016-03-01
MX366018B (es) 2019-06-24
CA2871955A1 (en) 2013-11-07
ES2878724T3 (es) 2021-11-19
CN104395463B (zh) 2018-07-31
US20170253857A1 (en) 2017-09-07
EP2844742B1 (en) 2018-11-21
BR112014027155B1 (pt) 2022-03-29
US9663763B2 (en) 2017-05-30
RU2018111729A (ru) 2019-02-28
CA2871955C (en) 2021-02-02
US11136549B2 (en) 2021-10-05
EP3447125A1 (en) 2019-02-27
AU2013256424B2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
MX2019007492A (es) Composiciones de celulas t deficientes del receptor de celulas t.
CY1124311T1 (el) Παρεμποδιστες dna-pk
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
BR112015027327A2 (pt) composições e métodos para alterar a sinalização do mensageiro secundário
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
NI201200029A (es) Compuestos y composiciones como inhibidores de cinasa de proteína
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
MX2016002571A (es) Regulador de ph de transduccion.
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112015021463A2 (pt) moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112014013138A2 (pt) anilinas substituídas como antagonistas de ccr(4)
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
BR112016029558A2 (pt) terapia de células-tronco em patologias endometriais